Toremifene – a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy

Bibliography

• JEMAL A, MURRAY T, WARD E, et al: Cancer statistics, 2005. CA Cancer J. Clin. (2005) 55(1):10-30.
   PubMed Web of Science ®Google Scholar
• BOSTWICK DG, BRAWER MK: Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer (1987) 59(4):788-794.
   Google Scholar
• STEINER MS. High-grade prostatic intraepithelial neoplasia and prostate cancer risk reduction. World J. Urol. (2003) 21(1):15-20.
   PubMed Web of Science ®Google Scholar
• SAKR WA, LUCIA MS: Potential pathologic markers for prostate chemoprevention studies. Urol. Clin. North Am. (2004) 31(2):227-235.
   PubMed Web of Science ®Google Scholar
• SCHLESINGER C, BOSTWICK DG, ICZKOWSKI KA: High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice. Am. J. Surg. Pathol. (2005) 29(9):1201-1207.
   PubMed Web of Science ®Google Scholar
• ZENG L, KYPRIANOU N: Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention. Prostate Cancer Prostatic Dis. (2005) 8(1):7-13.
   PubMed Web of Science ®Google Scholar
• LEFKOWITZ GK, TANEJA SS, BROWN J et al.: Follow up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J. Urol. (2002) 168(4 Part 1):1415-1418.
   PubMed Web of Science ®Google Scholar
• KELLOFF GJ, LIEBERMAN R, BRAWER MK et al.: Strategies for chemoprevention of prostate cancer. Prostate Cancer Prostatic Dis. (1999) 2(S1):27-33.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN R: Chemoprevention of prostate cancer: current status and future directions. Cancer Metastis. Rev. (2002) 21(3-4):297-309.
   Web of Science ®Google Scholar
• MOYAD MA, CARROLL PR: Lifestyle recommendations to prevent prostate cancer, part II: time to redirect our attention? Urol. Clin. North Am. (2004) 31(2)301-311.
   PubMed Web of Science ®Google Scholar
• STRATTON MS, REID ME, SCHWARTZBERG G et al.: Selenium and prevention of prostate cancer in high-risk men: the Negative Biopsy Study. Anticancer Drugs (2003) 14(8):589-594.
   PubMed Web of Science ®Google Scholar
• ANDRIOLE G, BOSTWICK D, BRAWLEY O et al.: Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J. Urol. (2004) 172(4 Part 1):1314-1317.
   PubMed Web of Science ®Google Scholar
• KLEIN EA, THOMPSON IM, LIPPMAN SM et al.: SELECT: the selenium and vitamin E cancer prevention trial. Urol. Oncol. (2003) 21:59-65.
   PubMed Web of Science ®Google Scholar
• GUPTA S: Prostate cancer chemoprevention: models, limitations and potential. Int. J. Oncol. (2004) 25:1133-1148.
   PubMed Web of Science ®Google Scholar
• THOMPSON IM, GOODMAN PJ, TANGEN CM et al.: The influence of finasteride in the development of prostate cancer. N. Engl. J. Med. (2003) 349:215-224.
   PubMed Web of Science ®Google Scholar
• BOSLAND MC: The role of steroid hormones in prostate carcinogenesis. J. Natl. Cancer Inst. Monogr. (2000) 27:39-66.
   PubMedGoogle Scholar
• HO SM: Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J. Cell Biochem. (2004) 91(3):491-503.
   PubMed Web of Science ®Google Scholar
• SUZUKI K, NAKAZATO H, MATSUI H et al.: Genetic polymorphisms of estrogen receptor α, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer (2003) 98(7):1411-1416.
   PubMed Web of Science ®Google Scholar
• SHARIFI N, GULLEY JL, DAHUT WL: Androgen deprivation therapy for prostate cancer. J. Am. Med. Assoc. (2005) 294(2):238-244.
   PubMed Web of Science ®Google Scholar
• LOBLAW DA, MENDELSON DS, TALCOTT JA et al: American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J. Clin. Oncol. (2004) 22(14):2927-2941.
   PubMed Web of Science ®Google Scholar
• SHAHINIAN VB, KUO YF, FREEMAN JL et al.: Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer (2005) 103(8):1615-1624.
   PubMed Web of Science ®Google Scholar
• STOCH SA, PARKER RA, CHEN L et al.: Bone Loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J. Clin. Endocrinol. Metab. (2001) 86(6):2787-2791.
   PubMed Web of Science ®Google Scholar
• KEY T, APPLEBY P, BARNES I et al.: Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. (2002) 94(8):606-616.
   PubMed Web of Science ®Google Scholar
• BRENNER H: Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet (2002) 360(9340):1131-1135.
   PubMed Web of Science ®Google Scholar
• LINDBERG MK, VANDENPUT L, MOVERARE SS et al: Androgens and the skeleton. Minerva Endocrinol. (2005) 30(1):15-25.
   PubMedGoogle Scholar
• ADAMS JY, LEAV I, LAU KM et al.: Expression of estrogen receptor β in the fetal, neonatal, and prepubertal human prostate. Prostate (2002) 52(1):69-81.
   PubMed Web of Science ®Google Scholar
• MULLER M, VAN DER SCHOUW YT, THIJSSEN JH et al: Endogenous sex hormones and cardiovascular disease in men. J. Clin. Endocrinol. Metab. (2003) 88(11):5076-5086.
   PubMed Web of Science ®Google Scholar
• KATZENELLENBOGEN BS, CHOI I, DELAGE-MOURROUX R et al: Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J. Steroid Biochem. Mol. Biol. (2000) 74(5):279-285.
   PubMed Web of Science ®Google Scholar
• YI P, DRISCOLL MD, HUANG J et al.: The effects of estrogen-responsive element- and ligand-induced structural changes on the recruitment of cofactors and transcriptional responses by ERα and ERβ. Mol. Endocrinol. (2002) 16(4):674-693.
   PubMed Web of Science ®Google Scholar
• BJORNSTROM L, SJOBERG M: Estrogen receptor-dependent activation of AP-1 via non-genomic signaling. Nucl. Recept. (2004) 2(1):3.
   PubMedGoogle Scholar
• SMITH CL, O’MALLEY BW: Coregulator function: a key to understanding tissue specificity of selective estrogen receptor modulators. Endocr. Rev. (2004) 25(1):45-71.
   PubMed Web of Science ®Google Scholar
• GLASS CK, ROSENFELD MG: The co-regulator exchange in transcriptional functions of nuclear receptors. Genes Dev. (2000) 14:121-141.
   PubMed Web of Science ®Google Scholar
• JAKACKA M, ITO M, WEISS J: Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J. Biol. Chem. (2001) 276(17):13615-13621.
   PubMed Web of Science ®Google Scholar
• SAFE S: Transcriptional activation of genes by 17-β-estradiol through estrogen receptor–Sp1 interactions. Vitam. Horm. (2001) 62:231-252.
   PubMed Web of Science ®Google Scholar
• McDONNELL DP, CHANG CY, NORRIS JD: Capitalizing on the complexities of estrogen receptor pharmacology in the quest for the perfect SERM. Ann. NY Acad. Sci. (2001) 949:16-35.
   PubMed Web of Science ®Google Scholar
• MEEGAN MJ, LLOYD DG: Advances in the science of estrogen receptor modulation. Curr. Med. Chem. (2003) 10(3):181-210.
   PubMed Web of Science ®Google Scholar
• HUBBARD RE, PIKE AC, BRZOZOWSKI AM et al.: Structural insights into the mechanisms of agonism and antagonism in oestrogen receptor isoforms. Eur. J. Cancer (2000) 36(Suppl. 4):S17-S18.
   PubMedGoogle Scholar
• MONROE DG, SECRETO FJ, SUBRAMANIAM M et al.: Estrogen receptor α and β heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol. Endocrinol. (2005) 19(6):1555-1568.
   PubMed Web of Science ®Google Scholar
• KIAN TEE M, ROGATSKY I, TZAGARAKIS-FOSTER C et al: Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol. Biol. Cell. (2004) 15(3):1262-1272.
   PubMed Web of Science ®Google Scholar
• QIAN YM, SUN XJ, TONG MH et al.: Targeted disruption of the mouse estrogen sulfotransferase gene reveals a role of estrogen metabolism in intracrine and paracrine estrogen regulation. Endocrinology (2001) 142(12):5342-5350.
   PubMed Web of Science ®Google Scholar
• PLATZ EA, GIOVANNUCCI E: The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J. Steroid Biochem. Mol. Biol. (2004) 92(4):237-253.
   PubMed Web of Science ®Google Scholar
• RISBRIDGER GP, BIANCO JJ, ELLEM SJ, McPHERSON SJ: Oestrogens and prostate cancer. Endocr. Relat. Cancer (2003) 10(2):187-91.
   PubMed Web of Science ®Google Scholar
• SORONEN P, LAITI M, TORN S et al: Sex steroid hormone metabolism and prostate cancer. J. Steroid Biochem. Mol. Biol. (2004) 92(4):281-286.
   PubMed Web of Science ®Google Scholar
• PRINS GS, BIRCH L, COUSE JF et al.: Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor α: studies with αERKO and βERKO mice. Cancer Res. (2001) 61(16):6089-6097.
   PubMed Web of Science ®Google Scholar
• LATIL AG, AZZOUZI R, CANCEL GS et al.: Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer (2001) 92(5):1130-1137.
   PubMed Web of Science ®Google Scholar
• ZHU X, LEAV I, LEUNG YK et al.: Dynamic regulation of estrogen receptor-β expression by DNA methylation during prostate cancer development and metastasis. Am. J. Pathol. (2004) 164(6):2003-2012.
   PubMed Web of Science ®Google Scholar
• DEMARZO AM, NELSON WG, ISAACS WB, EPSTEIN JI: Pathological and molecular aspects of prostate cancer. Lancet (2003) 361(9361):955-964.
   PubMed Web of Science ®Google Scholar
• MAKELA S, STRAUSS L, KUIPER G et al.: Differential expression of estrogen receptors α and β in adult rat accessory sex glands and lower urinary tract. Mol. Cell Endocrinol. (2000) 170(1-2):219-229.
   PubMed Web of Science ®Google Scholar
• LEAV I, LAU KM, ADAMS JY et al.: Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. (2001) 159(1):79-92.
   PubMed Web of Science ®Google Scholar
• FIXEMER T, REMBERGER K, BONKHOFF H: Differential expression of the estrogen receptor β (ERβ) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate (2003) 54(2):79-87.
   PubMed Web of Science ®Google Scholar
• SKLIRIS GP, MUNOT K, BELL SM et al.: Reduced expression of oestrogen receptor β in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J. Pathol. (2003) 201(2):213-220.
   PubMed Web of Science ®Google Scholar
• JI Q, LIU PI, ELSHIMALI Y, STOLZ A: Frequent loss of estrogen and progesterone receptors in human prostatic tumors determined by quantitative real-time PCR. Mol. Cell Endocrinol. (2005) 229(1-2):103-110.
   PubMed Web of Science ®Google Scholar
• LAU KM, LASPINA M, LONG J et al.: Expression of estrogen receptor (ER)-α and ER-β in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth retardation. Cancer Res. (2000) 60(12):3175-3182.
   PubMed Web of Science ®Google Scholar
• GUERINI V, SAU D, SCACCIANOCE E et al.: The androgen derivative 5α-androstane-3β,17β-diol inhibits prostate cancer cell migration through activation of the estrogen receptor β subtype. Cancer Res. (2005) 65(12):5445-5453.
   PubMed Web of Science ®Google Scholar
• SIGNORETTI S, LODA M: Estrogen receptor β in prostate cancer: brake pedal or accelerator? Am. J. Pathol. (2001) 159(1):13-16.
   PubMed Web of Science ®Google Scholar
• CHENG J, LEE EJ, MADISON LD, LAZENNEC G: Expression of estrogen receptor β in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett. (2004) 566(1-3):169-172.
   PubMed Web of Science ®Google Scholar
• IMAMOV O, MORANI A, SHIM GJ et al.: Estrogen receptor β regulates epithelial cellular differentiation in the mouse ventral prostate. Proc. Natl. Acad. Sci. USA (2004) 101(25):9375-9380.
   PubMed Web of Science ®Google Scholar
• BARDIN A, BOULLE N, LAZENNEC G et al.: Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr. Relat. Cancer (2004) 11(3):537-551.
   PubMed Web of Science ®Google Scholar
• RISBRIDGER G, WANG H, YOUNG P et al.: Evidence that epithelial and mesenchymal estrogen receptor-α mediates effects of estrogen on prostatic epithelium. Dev. Biol. (2001) 231(1):289.
   Web of Science ®Google Scholar
• COUSE JF, KORACH KS: Estrogen receptor-α mediates the detrimental effects of neonatal diethylstilbestrol (DES) exposure in the murine reproductive tract. Toxicology (2004) 205(1-2):55-63.
   PubMed Web of Science ®Google Scholar
• BRZOZOWSKI AM, PIKE AC, DAUTER Z et al.: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (1997) 389(6652)753-758.
   PubMed Web of Science ®Google Scholar
• SHIAU AK, BARSTAD D, LORIA PM et al.: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell (1998) 95(7):927-937.
   PubMed Web of Science ®Google Scholar
• KATO S, ENDOH H, MASUHIRO Y et al.: Activation of the estrogen receptor through phosphorylation by mitogen activated protein kinase. Science (1995) 270(5241):1491-1494.
   PubMed Web of Science ®Google Scholar
• BUNONE G, BRIAND PA, MIKSICEK RJ et al.: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. (1996) 15(9):2174-2183.
   PubMed Web of Science ®Google Scholar
• KONG EH, HELDRING N, GUSTAFSSON JA et al.: Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. Proc. Natl. Acad. Sci. USA (2005) 102(10):3593-3598.
   PubMed Web of Science ®Google Scholar
• LIU H, LEE E-S, DE LOS REYES A et al.: Silencing and reactivation of the selective estrogen receptor modulator a complex. Cancer Res. (2001) 61:3632-3639.
   PubMed Web of Science ®Google Scholar
• WOOD JR, GREENE GL, NARDULLI AM: Estrogen response elements function as allosteric modulators of estrogen receptor conformation. Mol. Cell Biol. (1998) 18(4):1927-1934.
   PubMed Web of Science ®Google Scholar
• KLINGE CM, JERNIGAN SC, MATTINGLY KA: Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors α and β by coactivators and corepressors. J. Mol. Endocrinol. (2004) 33(2):387-410.
   PubMed Web of Science ®Google Scholar
• ERIKSEN ER, COLVARD DS, BERG NJ et al.: Evidence of estrogen receptors in normal human osteoblast-like cells. Science (1988) 241(4861):84-86.
   PubMed Web of Science ®Google Scholar
• COLVARD DS, ERIKSEN EF, KEETING PE et al.: Identification of androgen receptors in normal human osteoblast-like cells. Proc. Natl. Acad. Sci. USA (1989) 86(3):854-857.
   PubMed Web of Science ®Google Scholar
• OURSLER MJ, LANDERS JP, RIGGS BL et al.: Oestrogen effects on osteoblasts and osteoclasts. Ann. Med. (1993) 25(4):361-371.
   PubMed Web of Science ®Google Scholar
• MIZUNO Y, HOSOI T, INOUE S et al.: Immunocytochemical identification of androgen receptor in mouse osteoclast-like multinucleated cells. Calcif. Tissue Int. (1994) 54(4):325-326.
   PubMed Web of Science ®Google Scholar
• OURSLER MJ, OSDOBY P, PYFFEROEN J et al.: Avian osteoclasts as estrogen target cells. Proc. Natl. Acad. Sci. USA (1991) 88(15):6613-6617.
   PubMed Web of Science ®Google Scholar
• SPELSBERG TC, SUBRAMANIAM M, RIGGS BL, KHOSLA S: The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol. Endocrinol. (1999) 13(6):819-828.
   PubMed Web of Science ®Google Scholar
• FALAHATI-NINI A, RIGGS BL, ATKINSON EJ et al.: Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J. Clin. Invest. (2000) 106(12):1553-1560.
   PubMed Web of Science ®Google Scholar
• LEDER BZ, LEBLANC KM, SCHOENFELD DA et al.: Differential effects of androgens and estrogens on bone turnover in normal men. J. Clin. Endocrinol. Metab. (2003) 88(1):204-210.
   PubMed Web of Science ®Google Scholar
• KHOSLA S, MELTON III LJ, RIGGS BL: Clinical review 144: estrogen and the male skeleton. J. Clin. Endocrinol. Metab. (2002) 87(4):1443-1450.
   PubMed Web of Science ®Google Scholar
• CARLSEN CG, SOERENSEN TH, ERIKSEN EF: Prevalence of low serum estradiol levels in male osteoporosis. Osteoporos. Int. (2000) 11(8):697-701.
   PubMed Web of Science ®Google Scholar
• GENNARI L, MERLOTTI D, MARTINI G et al.: Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J. Clin. Endocrinol. Metab. (2003) 88(11):5327-5333.
   PubMed Web of Science ®Google Scholar
• CARLSTROM K, STEGE R, HENRICKSSON P et al.: Possible bone-preserving capacity of high-dose depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma. Prostate (1997) 31(3):193-197.
   PubMed Web of Science ®Google Scholar
• ERIKSSON S, ERIKSSON A, STEGE R, CARLSTROM K: Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif. Tissue Int. (1995) 57(2):97-99.
   PubMed Web of Science ®Google Scholar
• HOFBAUER LC, SCHOPPET M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. J. Am. Med. Assoc. (2004) 292(4):490-495.
   PubMed Web of Science ®Google Scholar
• DIAMOND T, CAMPBELL J, BRYANT C et al.: The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer (1998) 83(8):1561-1566.
   PubMed Web of Science ®Google Scholar
• MAILLEFERT JF, SIBILIA J, MICHEL F et al.: Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J. Urol. (1999) 161:1219-1222.
   PubMed Web of Science ®Google Scholar
• DANIELL HW: Osteoporosis after orchiectomy for prostate cancer. J. Urol. (1997) 157(2):439-444.
   PubMed Web of Science ®Google Scholar
• SMITH MR, McGOVERN FJ, ZIETMAN AL et al.: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. (2001) 345:948-955.
   PubMed Web of Science ®Google Scholar
• BERRUTI A, DOGLIOTTI L, TERRONE C et al.: Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J. Urol. (2002) 167:2361-2367.
   PubMed Web of Science ®Google Scholar
• SMITH MR, EASTHAM J, GLEASON D et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol. (2003) 169:2008-2012.
   PubMed Web of Science ®Google Scholar
• SMITH MR, FALLON MA, LEE H et al.: Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J. Clin. Endocrinol. Metab. (2004) 89:3841-3846.
   PubMed Web of Science ®Google Scholar
• LEE H, McGOVERN K, FINKELSTEIN JS et al.: Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate cancer. Cancer (2005) 104(8):1633-1637.
   PubMed Web of Science ®Google Scholar
• SMITH MR, LEE WC, KRUPSKI T et al.: Association between androgen deprivation therapy and fracture risk: a population-based cohort study in men with nonmetastatic prostate cancer. Proc. Am. Soc. Clin. Oncol. USA (2004) (Abstract 4507).
   Google Scholar
• SHAHINIAN VB, KUO YF, FREEMAN JL, GOODWIN JS: Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. (2005) 352(2):154-164.
   PubMed Web of Science ®Google Scholar
• SMITH M, BOYCE S, MOYNEUR E et al.: Risk of clinical fracture after gonadotropin-releasing hormone agonist therapy for prostate cancer. J. Urol. (2006) 175(1):136-139 (Discussion 139).
   PubMed Web of Science ®Google Scholar
• SMITH M, LEE W, BRANDMAN J et al.: Gonadotropin-releasing hormone (GnRH) agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J. Clin. Oncol. (2005) 23(31):7897-7903.
   PubMed Web of Science ®Google Scholar
• TOWNSEND MF, SANDERS WH, NORTHWAY RO et al.: Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer (1997) 79:545-550.
   PubMed Web of Science ®Google Scholar
• HATANO T, OISHI Y, FURUTA A et al.: Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer [in process citation]. BJU Int. (2002) 86:449-452.
   Web of Science ®Google Scholar
• OEFELEIN MG, RICCHUITI V, CONRAD W et al.: Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J. Urol. (2001) 166:1724-1728.
   PubMed Web of Science ®Google Scholar
• MELTON LJ III, ALOTHMAN KI, KHOSLA S et al.: Fracture risk following bilateral orchiectomy. J. Urol. (2003) 169:1747-1750.
   PubMed Web of Science ®Google Scholar
• DICKMAN PW, ADOLFSSON J, ASTROM K, et al: Hip fractures in men with prostate cancer treated with orchiectomy. J. Urol. (2004) 172:2208-2212.
   PubMed Web of Science ®Google Scholar
• TEILLAC P, BONO AV, IRANI J, WIRTH MP, ZLOTTA AR: The role of luteinizing hormone-releasing therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use. Clin. Ther. (2005) 27(3):273-285.
   PubMed Web of Science ®Google Scholar
• ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J. Am. Med. Assoc. (1999) 282(7):637-645.
   PubMed Web of Science ®Google Scholar
• Evista® (raloxifene citrate), tablet product information: Physician’s Desk Reference, 59th Edition, Thompson PDR, Montvale, NJ, USA (2005):1915-1919.
   Google Scholar
• Nolvadex® (tamoxifen citrate), tablet product information: Physician’s Desk Reference, 59th Edition, Thompson PDR, Montvale, NJ, USA (2005):662.
   Google Scholar
• Fareston® (toremifene citrate), tablet product information: Physician’s Desk Reference, 59th Edition, Thompson PDR, Montvale, NJ, USA (2005):3139-3141.
   Google Scholar
• JOHANSEN AM: Breast cancer chemoprevention: a review of selective estrogen receptor modulators. Clin. J. Oncol. Nurs. (2005) 9(3):317-320.
   PubMedGoogle Scholar
• DUNN BK, FORD LG: From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J. (2001) 7(3):144-157.
   PubMedGoogle Scholar
• MAHAKALA A, THOUTREDDY S, KLEEREKOPER M: Prevention and treatment of postmenopausal osteoporosis. Treat. Endocrinol. (2003) 2(5):331-345.
   PubMedGoogle Scholar
• TERMINE JD, WONG M: Post-menopausal women and osteoporosis: available choices for maintenance of skeletal health. Maturitas (1998) 30(3):241-245.
   PubMed Web of Science ®Google Scholar
• NEUBAUER BL, McNULTY AM, CHEDID M et al.: The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model. Cancer Res. (2003) 63(18):6056-6062.
   PubMed Web of Science ®Google Scholar
• ROHLFF C, BLAGOSKLONNY MV, KYLE E et al.: Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1. Prostate (1998) 37:51-59.
   PubMed Web of Science ®Google Scholar
• EL ETREBY MF, LIANG Y, LEWIS RW: Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate (2000) 43(1):31-42.
   PubMed Web of Science ®Google Scholar
• KIM IY, SEONG DO H, KIM BC et al.: Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell lines LNCaP through an androgen-independent pathway. Cancer Res. (2002) 62(13):3649-3653.
   PubMed Web of Science ®Google Scholar
• KIM IY, KIM BC, SEONG DO H et al.: Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res. (2002) 62(18):5365-5369.
   PubMed Web of Science ®Google Scholar
• WOODHAM C, BIRCH L, PRINS GS: Neonatal estrogen down-regulates prostatic androgen receptor through a proteosome-mediated protein degradation pathway. Endocrinology (2003) 144(11):4841-4851.
   PubMed Web of Science ®Google Scholar
• NELLEMANN C, DALGAARD M, HOLST B et al.: Gene expression changes in rat prostate after activation or blocking of the androgen and estrogen receptor. Mol. Cell Endocrinol. (2005) 237(1-2):25-35.
   PubMed Web of Science ®Google Scholar
• ZENG Y, YOKOHIRA M, SAOO K et al.: Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor. Carcinogenesis (2005) 26(6):1109-1116.
   PubMed Web of Science ®Google Scholar
• KAWASHIMA H, TANAKA T, CHENG JS, et al: Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells. Urol. Res. (2004) 32(6):406-410.
   PubMed Web of Science ®Google Scholar
• MA ZS, HUYNH TH, NG CP, DO PT, NGUYEN TH, HUYNH H: Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercitin treatment is associated with inhibition of angiogenesis and cellular proliferation. In. J. Oncol. (2004) 24(5):1297-1304.
   Web of Science ®Google Scholar
• RAGHOW S, HOOSHDARAN MZ, KATIYAR S, STEINER MS: Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. (2002) 62:1370-1376.
   PubMed Web of Science ®Google Scholar
• GREENBERG NM, DEMAYO F, FINEGOLD MJ et al.: Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA (1995) 92:3439-3443.
   PubMed Web of Science ®Google Scholar
• KAPLAN-LEFKO PJ, CHEN TM, ITMANN MM et al.: Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate (2003) 55(3):219-237.
   PubMed Web of Science ®Google Scholar
• STEINER MS, POUND CR: Phase IIA clinical trial to test the efficacy and the safety of toremifene in men with high-grade prostatic intraepithelial neoplasia. Clin. Prostate Cancer (2003) 2:24-31.
   PubMedGoogle Scholar
• FDA: Summary basis of approval, toremifene citrate (Fareston) (1997).
   Google Scholar
• SIPILA H, NANTO V, KANGAS L et al.: Binding of toremifene to human serum proteins. Pharmacol. Toxicol. (1988) 63(1):62-64.
   PubMedGoogle Scholar
• KANGAS L: Biochemical and pharmacological effects of toremifene and metabolites. Cancer Chemother. Pharmacol. (1990) 27(1):8-12.
   PubMed Web of Science ®Google Scholar
• BERTHOU F, DREANO Y, BELLOC C, KANGAS L, GAUTIER JC, BEAUNE P: Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem. Pharmacol. (1994) 47(10):1883-1895.
   PubMed Web of Science ®Google Scholar
• SIPILA H, KANGAS L, VUORILEHTO L et al.: Metabolism of toremifene in the rat. J. Steroid Biochem. (1990) 36(3):211-215.
   PubMedGoogle Scholar
• ANTTILA M, VALAVAARA R, KIVINEN S, MAENPAA J: Pharmacokinetics of toremifene. J. Steroid Biochem. (1990) 36(3):249-252.
   PubMedGoogle Scholar
• TOMINAGA T, ABE O, IZUO M, NOMURA Y: A phase I study of toremifene. Breast Cancer Res. Treat. (1990) 16:S27-S29.
   PubMed Web of Science ®Google Scholar
• MORELLO KC, WURZ GT, DEGREGORIO MW: Pharmacokinetics of selective estrogen modulators. Clin. Pharmacokinet. (2003) 42(4):361-372.
   PubMed Web of Science ®Google Scholar
• TARAS TL, WURZ GT, LINARES GR, DEGREGORIO MW: Clinical pharmacokinetics of toremifene. Clin. Pharmacokinet. (2000) 39(5):327-334.
   PubMed Web of Science ®Google Scholar
• WISEMAN LR, GOA KL: Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Drugs (1997) 54(1):141-160.
   PubMed Web of Science ®Google Scholar
• KOHLER PC, HAMM JT, WIEBE VJ, DE GREGORIO MW, SHEMANO I, TORMEY DC: Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer. Breast Cancer Res. Treat. (1990) 16:S19-S26.
   PubMed Web of Science ®Google Scholar
• BISHOP J, MURRAY R, WEBSTER L et al.: Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer. Cancer Chemother. Pharmacol. (1992) 30(3):174-178.
   PubMed Web of Science ®Google Scholar
• WIEBE VJ, BENZ CC, SHEMANO I et al.: Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother. Pharmacol. (1990) 25(4):247-251.
   PubMed Web of Science ®Google Scholar
• ANTTILA M, LAAKSO S, NYLANDEN P, SOTANIEMI EA: Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function. Clin. Pharmacol. Ther. (1995) 57(6):628-635.
   PubMed Web of Science ®Google Scholar
• KIVISTO KT, VILLIKKA K, NUMAN L, ANTTILA M, NEUVONEN PJ: Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin. Pharmacol. Ther. (1998) 64(6):648-654.
   PubMed Web of Science ®Google Scholar
• WURZ GT, SOC L, EMSHOFF VD, CADMAN TB, DEGREGORIO MW: Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin. Cancer Chemother. Pharmacol. (1998) 42(5):363-366.
   PubMed Web of Science ®Google Scholar
• MAENPAA JU, ALA-FOSSI SL: Toremifene in postmenopausal breast cancer. Efficacy, safety, and cost. Drugs Aging (1997) 11(4):261-270.
   PubMed Web of Science ®Google Scholar
• HOLLI K, VALAVAARA R, BLANCO G et al.: Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J. Clin. Oncol. (2000) 18(20):3487-3494.
   PubMed Web of Science ®Google Scholar
• STEIN S, ZOLTICK B, PEACOCK T et al.: Phase II trial of toremifene in androgen-independent prostate cancer: a Penn cancer clinical trials group trial. Am. J. Clin. Oncol. (2001) 24(3):283-285.
   PubMed Web of Science ®Google Scholar
• STEIN B, ZINNER N, ISRAELI RS, WAKE R, MITCHELL J, STEINER MS: Effects of toremifene on hormones in men treated for 1 year in a double-blind, placebo-controlled study. J. Urol. (2005) 173(4):272 (Abstract 1004).
   Google Scholar
• PRICE D, STEIN B, SIEBER P et al.: Toremifene for the prevention of prostate cancer among men with high-grade prostatic intraepithelial neoplasia: results of a double-blind, placebo-controlled, Phase IIB clinical trial. J. Clin. Oncol. (2005) 23:106.
   Google Scholar
• CLARK RV, HERMANN DJ, CUNNINGHAM GR, WILSON TH, MORRILL BB, HOBBS S: Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 α-reductase inhibitor. J. Clin. Endocrinol. Metab. (2004) 89(5):2179-2184.
   PubMed Web of Science ®Google Scholar
• KUIPER GJ, KUIPER M, CARLSSON B et al.: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptor α and β. Endocrinology (1997) 138(3):863-870.
   PubMed Web of Science ®Google Scholar
• BRADY H, DOUBLEDAY M, GAYO-FUNG LM et al.: Differential response of estrogen receptors α and β to SP500263, a novel potent selective estrogen receptor modulator. Mol. Pharmacol. (2002) 61(3):562-568.
   PubMed Web of Science ®Google Scholar
• PRICE D, ISRAELI R, BOGER R, STEINER MS: Concentration-dependent estrogen receptor binding profile of toremifene may account for its clinical dose-response profile. J. Urol. (2005) 173(4):274 (Abstract 1012).
   Google Scholar
• WEIHUA Z, MAKELA S, ANDERSSON LC et al.: A role for estrogen receptor β in the regulation of growth of the ventral prostate. Proc. Natl. Acad. Sci. USA (2001) 98(11):6330-6335.
   PubMed Web of Science ®Google Scholar
• HARRIS DM, BESSELINK E, HENNING SM et al.: Phytoestrogens induce differential estrogen α- or β-mediated responses in transfected breast cancer cells. Exp. Biol. Med. (Maywood) (2005) 230(8):558-568.
   PubMed Web of Science ®Google Scholar
• STEINER MS, PATTERSON A, ISRAELI R et al.: Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deptivation therapy in patients with prostate cancer. J. Clin. Oncol. (2004) 22:4065 (Suppl. 4597).
   Google Scholar